KIBOW Celebrates 25 Years of Microbiome R&D Focusing on CKD Patients

NEWTOWN SQUARE, Pa., Sept. 30, 2022 /PRNewswire/ — Kibow Biotech, Inc., a clinical-stage biotechnology company developing live biotherapeutics that target the dysbiosis in patients with CKD, today celebrated a 25-year legacy of dedication to improving the lives of patients with kidney…

Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.